IHC Detection Kits & c-Myc Antibodies: Core Tools for Modern Pathological Diagnosis and Tumor Immunology Research

Concept

Modern pathological diagnosis and tumor research rely on two synergistic technological pillars: standardized immunohistochemistry (IHC) detection systems that enable precise in situ protein localization and semi-quantification in tissue samples, and high-specificity target antibodies that detect key oncogenic molecules driving tumor progression and immune evasion. IHC kits provide a standardized, reproducible platform for antigen-antibody binding and signal visualization—an indispensable technique for clinical pathological diagnosis and translational research. c-Myc, a master proto-oncogenic transcription factor, is a central node in tumor biology, whose aberrant overexpression drives cell proliferation, metabolic reprogramming and immunosuppressive tumor microenvironment (TME) remodeling, making it a critical target for tumor research and immunotherapy development. Together, validated IHC kits and c-Myc-specific antibodies form a powerful integrated toolchain for accurate protein detection, pathological classification, and mechanistic dissection of tumor biology. As a global leader in life science reagents, ANT BIO PTE. LTD. delivers industry-leading solutions for both areas via its specialized sub-brands: the Absin sub-brand (for general reagents and kits) offers high-performance IHC detection kits, and the Starter sub-brand (for flagship antibodies) provides ultra-specific c-Myc recombinant rabbit monoclonal antibodies. All products are rigorously validated for sensitivity, specificity and batch consistency, serving as gold-standard tools for clinical pathology, tumor immunology, precision oncology and basic life science research worldwide.

Research Frontiers

IHC technology and c-Myc tumor research are at the cutting edge of modern pathology and oncology, driving breakthroughs in clinical diagnosis, personalized treatment and mechanistic understanding of tumorigenesis. ANT BIO PTE. LTD.’s IHC detection kits and c-Myc antibodies enable transformative discoveries in key high-impact research and clinical frontiers that are redefining pathological diagnosis and tumor therapy:

Immunohistochemistry (IHC) Kit Technology

1. Multiplex IHC detection: Development of simultaneous multi-marker staining systems to map complex protein expression patterns in the TME, enabling spatial analysis of tumor-immune cell interactions.
2. Automation and AI-assisted analysis: Integration of IHC kits with automated staining platforms and artificial intelligence (AI) image analysis tools to eliminate subjective interpretation and enable precise quantitative protein expression analysis.
3. Companion diagnostic (CDx) development: Engineering standardized IHC kits for predictive biomarker detection (e.g., ER/PR/HER2 in breast cancer, PD-L1 in immunotherapy) to guide targeted therapy selection and treatment response prediction.
4. Technology fusion with spatial omics: Combining IHC with spatial transcriptomics and mass spectrometry imaging to correlate protein expression with gene transcription and metabolite distribution in intact tissue sections.
5. Standardization of pre-analytical and analytical workflows: Establishing global quality control (QC) standards for tissue processing, antigen retrieval and staining to ensure inter-laboratory reproducibility of IHC results.

c-Myc in Tumor Immunology and Oncogenic Regulation

1. c-Myc-mediated TME remodeling: Dissecting the molecular mechanisms by which c-Myc overexpression polarizes tumor-associated macrophages (TAMs) to an immunosuppressive phenotype, inhibits effector T cell infiltration and upregulates immune checkpoints (e.g., PD-L1) in tumor cells.
2. Targeting intratumoral c-Myc heterogeneity: Developing smart genetic circuits and exosome-based delivery systems that sense c-Myc expression levels to overcome immunotherapy resistance caused by heterogeneous c-Myc expression in solid tumors and hematologic malignancies.
3. c-Myc-targeted combination immunotherapy: Exploring synergistic effects of c-Myc inhibition with immune checkpoint inhibitors (ICIs), CAR-T cell therapy and cytokine therapies to reverse TME immunosuppression and enhance anti-tumor immune responses.
4. c-Myc post-translational modification (PTM) research: Studying how phosphorylation (e.g., Ser62) and other PTMs regulate c-Myc stability, transcriptional activity and oncogenic function—identifying novel therapeutic targets for selective c-Myc modulation.
5. c-Myc as a predictive and prognostic biomarker: Validating c-Myc expression levels (detected via IHC with specific antibodies) as a clinical biomarker for tumor grading, metastasis prediction and treatment response assessment in various malignancies.

Research Significance

IHC detection kits and c-Myc-specific antibodies are indispensable tools in modern pathology and oncology, with their combined use driving paradigm shifts in clinical diagnosis, personalized medicine and our understanding of tumor biology. ANT BIO PTE. LTD.’s optimized IHC kits and high-performance c-Myc antibodies amplify the scientific and clinical significance of this research, with far-reaching implications for patient care and tumor therapy development:

IHC Detection Kits: The Foundation of Modern Pathological Diagnosis

1. Gold-standard for in situ protein detection: IHC is the only technique that enables visual localization and semi-quantification of proteins in intact tissue sections, preserving spatial context critical for understanding tissue architecture and tumor microenvironment interactions—an essential feature missing from bulk molecular assays (e.g., Western blot, PCR).
2. Indispensable for clinical tumor classification and differential diagnosis: IHC kits enable specific marker detection (e.g., CK7/CK20 for epithelial cancer subtyping, CD markers for lymphoma classification) to distinguish tumor types, determine tissue origin and guide pathological grading—an essential step in clinical diagnosis and treatment planning.
3. Key to predictive biomarker testing: Standardized IHC kits are used worldwide to detect predictive biomarkers (e.g., ER/PR/HER2 in breast cancer, ALK in lung cancer) that identify patients who will benefit from targeted therapies, forming the basis of precision oncology.
4. Bridging basic research and clinical translation: IHC kits enable validation of novel biomarkers discovered in basic research on clinical tissue samples, accelerating the translation of scientific discoveries into clinical diagnostic tools and therapeutic targets.
5. Cost-effective and widely accessible: IHC is a relatively low-cost, easy-to-implement technique that is accessible to clinical pathology labs worldwide, making it the most widely used protein detection method in clinical practice and translational research.

c-Myc Antibodies: Unlocking the Mechanisms of Oncogenic Regulation and Tumor Immune Evasion

1. c-Myc as a master oncogenic regulator: Aberrantly overexpressed in >70% of human malignancies, c-Myc regulates the expression of >15% of all human genes to drive cell proliferation, metabolic reprogramming (Warburg effect, glutamine addiction) and cell survival—making it a central target for understanding the core oncogenic program of cancer.
2. Linking cell-intrinsic oncogenicity to TME immunosuppression: c-Myc is the key transcriptional node that connects tumor cell-autonomous oncogenic processes to TME remodeling, directly regulating immune checkpoint expression and immune cell infiltration—providing a unique target for combining oncogene inhibition and immunotherapy.
3. Essential for accurate tumor characterization: c-Myc-specific antibodies enable precise detection of c-Myc expression levels in tumor tissues (via IHC, WB and IF), providing critical information for tumor grading, prognosis assessment and molecular classification—guiding personalized treatment decisions for cancer patients.
4. Core tool for mechanistic tumor research: c-Myc antibodies are indispensable for studying c-Myc’s transcriptional regulatory network (via ChIP), protein-protein interactions (via Co-IP) and subcellular localization—unraveling the molecular mechanisms of c-Myc-mediated tumor progression and immune evasion.
5. Key to evaluating c-Myc-targeted therapy efficacy: c-Myc antibodies enable monitoring of c-Myc expression changes during targeted therapy, providing a direct readout of treatment efficacy and enabling early prediction of drug resistance development in preclinical and clinical studies.

Together, standardized IHC detection kits and high-specificity c-Myc antibodies form an integrated toolchain that is essential for translating basic tumor research into clinical diagnosis and personalized therapy, driving progress in precision oncology and improving patient outcomes worldwide.

Related Mechanisms, Research Methods & Product Applications

1. Immunohistochemistry (IHC) Kits: Core Principles, Components and Clinical Applications

IHC is a powerful histological technique that leverages the specific antigen-antibody binding reaction to detect and localize target proteins in intact tissue sections (formalin-fixed paraffin-embedded (FFPE), frozen) and cell smears. Modern IHC kits are systematically designed, standardized detection systems that optimize every step of the IHC workflow to ensure sensitivity, specificity and reproducibility of results.

Core Working Principle

1. Antigen retrieval: Chemical or thermal treatment of tissue sections to reverse protein cross-linking caused by formalin fixation and expose hidden target epitopes—an essential step for efficient primary antibody binding.
2. Primary antibody binding: Specific primary antibodies bind to target antigens in the tissue section to form stable immune complexes.
3. Signal amplification: Enzyme-conjugated secondary antibodies or polymer amplification systems amplify the weak antigen-antibody signal to detectable levels (e.g., HRP-polymer conjugates, biotin-streptavidin systems).
4. Chromogenic visualization: The enzyme catalyst (e.g., HRP) reacts with a chromogenic substrate (e.g., DAB, AEC) to produce an insoluble, colored precipitate at the site of antigen-antibody binding—enabling direct visual localization of the target protein under a light microscope.
5. Counterstaining and mounting: Hematoxylin counterstaining labels cell nuclei, and mounting preserves the tissue section for long-term storage and analysis.

Key Modular Components of IHC Kits

1. Antibody system: Validated primary antibodies (target-specific) and matched secondary antibodies (enzyme-labeled or polymer-based) optimized for minimal non-specific binding.
2. Signal amplification system: HRP-polymer conjugates or biotin-streptavidin complexes that enhance signal intensity for low-abundance antigen detection.
3. Chromogenic system: Stable enzyme substrates (e.g., DAB for brown precipitate, AEC for red precipitate) and substrate buffers for consistent color development.
4. Buffer system: Pre-optimized wash buffers, blocking solutions (to eliminate non-specific binding) and antigen retrieval reagents (citrate buffer, EDTA buffer) tailored for different tissue types and antigens.
5. Quality control system: Positive/negative control tissues or reagents to validate staining specificity and ensure experimental reliability.

Core Clinical and Research Applications of IHC Kits

1. Tumor classification and differential diagnosis: Distinguishing epithelial vs. non-epithelial tumors, determining metastatic tumor tissue origin and subtyping malignancies (e.g., CK7/CK20 for gastrointestinal adenocarcinoma subtyping).
2. Predictive and prognostic biomarker detection: Detecting ER/PR/HER2 (breast cancer), PD-L1 (immunotherapy), Ki-67 (proliferation index) and other biomarkers to guide targeted therapy selection and assess patient prognosis.
3. Infectious disease diagnosis: Identifying pathogen antigens (e.g., viruses, bacteria, fungi) in tissue sections for etiological diagnosis of infectious diseases.
4. Immunological disease typing: Detecting CD markers (e.g., CD3, CD4, CD20) for classification of lymphomas, leukemias and other immune system disorders.
5. Basic life science research: In situ protein localization and semi-quantification in normal and pathological tissues for studies of cell biology, developmental biology, neurobiology and tumor biology.

2. c-Myc: Molecular Function, Oncogenic Mechanisms and Antibody Applications

c-Myc is a 60-65 kDa proto-oncogenic transcription factor encoded by the MYC gene, a master regulator of cell proliferation, differentiation, metabolic reprogramming and apoptosis. As a core transcriptional factor, c-Myc forms heterodimers with Max to bind E-box motifs in the promoter regions of target genes, orchestrating a vast gene network that controls core cellular processes. In cancer cells, aberrant c-Myc overexpression or gene amplification drives tumor initiation, progression and immune evasion through four key mechanisms:

• Uncontrolled cell proliferation: Upregulates genes involved in cell cycle progression (cyclins, CDKs) and inhibits cell cycle checkpoints, promoting rapid, unregulated tumor cell division.
• Metabolic reprogramming: Induces the Warburg effect (aerobic glycolysis) and glutamine addiction, meeting the high energy and biosynthetic demands of rapidly proliferating tumor cells while depleting nutrients in the TME to inhibit immune cell function.
• TME immunosuppression: Upregulates PD-L1 and other immune checkpoint molecules on tumor cells, polarizes TAMs to an immunosuppressive M2 phenotype and inhibits the infiltration and activation of effector T cells and natural killer (NK) cells.
• Intratumoral heterogeneity: Heterogeneous c-Myc expression across tumor cell subpopulations creates distinct immunosuppressive TME regions, leading to treatment resistance and tumor recurrence after therapy.

Core Applications of c-Myc Antibodies (Coupled with IHC Kits)

c-Myc-specific antibodies are versatile research tools that perform excellently across multiple experimental platforms, with their most impactful clinical application being IHC detection in tumor tissues (when paired with a high-performance IHC kit). Key applications include:

1. IHC detection in tumor tissues: The gold-standard clinical application—c-Myc antibodies paired with IHC kits enable precise nuclear localization and semi-quantification of c-Myc in FFPE tumor sections, providing critical data for tumor grading, prognosis assessment and molecular classification in clinical pathology.
2. Western blot (WB): Detection of c-Myc protein expression levels in tumor cell lysates and tissue homogenates, enabling quantitative analysis of c-Myc expression changes during therapy or under experimental conditions.
3. Immunofluorescence (IF): Co-localization analysis of c-Myc with other oncogenic or immune molecules in cultured cells and frozen tissue sections, revealing subcellular localization and protein interaction dynamics.
4. Chromatin immunoprecipitation (ChIP): Identification of c-Myc’s direct target genes and genome-wide binding sites, dissecting the c-Myc-mediated transcriptional regulatory network in cancer cells.
5. Co-immunoprecipitation (Co-IP): Capture of c-Myc-interacting protein complexes (e.g., Max, transcriptional co-factors), unraveling the protein-protein interaction networks that regulate c-Myc function.
6. Therapy response monitoring: WB and IHC detection of c-Myc expression changes during c-Myc-targeted therapy or immunotherapy, enabling evaluation of treatment efficacy and early prediction of drug resistance.

ANT BIO PTE. LTD.’s Core Products: IHC Detection Kits (Absin) & c-Myc Antibodies (Starter)

ANT BIO PTE. LTD. offers a synergistic portfolio of high-performance IHC detection kits (Absin sub-brand: general reagents and kits) and ultra-specific c-Myc recombinant rabbit monoclonal antibodies (Starter sub-brand: flagship antibodies)—both rigorously validated for sensitivity, specificity, batch consistency and application performance. These products are optimized for seamless integration, forming a powerful toolchain for IHC detection of c-Myc in tumor tissues and comprehensive c-Myc research across all experimental platforms.

1. Absin Anti-Rabbit and Mouse HRP-DAB IHC Detection Kit (S0C1001)

A universal, high-performance IHC detection kit from the Absin sub-brand, designed for sensitive and specific detection of target proteins (including c-Myc) in FFPE/frozen tissue sections and cell smears. This kit features optimized HRP-polymer conjugates and high-purity DAB substrate, compatible with all rabbit/mouse primary antibodies (including the Starter c-Myc antibody).

Core Product Advantages

Key Application Values

• Clinical Pathology: Standardized DAB staining for tumor biomarkers (c-Myc, ER/PR/HER2, Ki-67, PD-L1) in clinical diagnostic labs—enabling tumor classification, prognostic assessment and targeted therapy selection.
• c-Myc IHC Detection: The ideal pairing with the Starter c-Myc rabbit mAb for precise nuclear localization and semi-quantification of c-Myc in FFPE tumor sections (lymphoma, breast, lung, colorectal cancer).
• Biomarker Development: Validating novel tumor biomarkers on tissue microarrays (TMAs) and clinical samples for translational research.
• Basic Life Science Research: In situ protein localization and semi-quantification for cell biology, developmental biology and tumor biology research.
• Education & Training: Reliable, consistent staining for pathology and histology teaching programs and laboratory technician training.

2. Starter S-RMab® c-Myc Recombinant Rabbit Monoclonal Antibody (S0B2165)

A flagship ultra-specific c-Myc antibody from the Starter sub-brand, engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform. This antibody is highly specific for c-Myc (minimal cross-reactivity to N-Myc/L-Myc) with broad cross-species applicability (human, mouse, rat) and optimized performance across WB, IHC, IF and ChIP— the gold-standard tool for c-Myc research.

Core Product Advantages

Key Research Application Values

• Tumor Pathology & Biomarker Detection: Paired with the Absin IHC kit for c-Myc detection in FFPE tumor tissues (lymphoma, breast, lung, colorectal cancer)—aiding pathological diagnosis, tumor grading, prognosis assessment and molecular classification.
• Oncogenic Mechanism Research: ChIP and Co-IP to dissect the c-Myc-mediated transcriptional regulatory network and protein-protein interaction pathways in cancer cells.
• Metabolic Reprogramming Research: Studying c-Myc’s role in driving the Warburg effect and glutamine addiction—uncovering the link between c-Myc and tumor cell metabolic abnormalities.
• Cell Proliferation & Stem Cell Research: Analyzing c-Myc’s regulation of cell cycle progression, stem cell self-renewal and differentiation in normal and cancerous cells.
• Targeted Drug Development: Screening and evaluating the efficacy of c-Myc-targeted drugs (small molecule inhibitors, PROTACs) and monitoring c-Myc expression changes during therapy—validating drug mechanism of action in preclinical studies.

Brand Mission of ANT BIO PTE. LTD.

At ANT BIO PTE. LTD., our core mission is to empower breakthroughs in modern pathological diagnosis, tumor biology, immunology and precision oncology by delivering high-quality, standardized and rigorously validated life science reagents and comprehensive solutions. We have built three specialized, complementary sub-brands that cover the full spectrum of life science research and clinical diagnostic needs, creating a seamless one-stop procurement experience for clinical pathologists, academic researchers, biotech companies, pharmaceutical institutions and translational research labs worldwide:

• Starter: Our flagship sub-brand for high-performance, ultra-specific antibodies and affinity tools. Specializes in recombinant rabbit/mouse monoclonal antibodies for key targets in tumor biology (c-Myc, EpCAM, PSMA), immunology (PD-L1), glycosylation (O-GlcNAc) and neurodegenerative diseases (PSEN1). All antibodies are rigorously validated for multi-platform performance and batch consistency, serving as gold-standard tools for basic research and clinical translation.
• Absin: Our core sub-brand for general life science reagents and standardized detection kits. Offers a comprehensive portfolio of IHC detection kits, ELISA kits, sample preparation reagents, cell culture media and biochemicals. Focuses on standardization, user-friendliness and reproducibility, providing essential reagents for clinical pathology labs and basic research facilities.
• UA: Our specialized sub-brand for high-purity, high-activity recombinant proteins and expression vectors. Specializes in recombinant cytokines, growth factors, antibody heavy/light chain constructs, immunomodulatory proteins and gene editing vectors. Enables seamless experimental design for protein expression, antibody engineering, cell therapy research and recombinant protein production for basic and biopharmaceutical applications.

We are committed to addressing the most pressing technical challenges in clinical pathology and tumor research—from standardizing IHC workflows and improving diagnostic reproducibility to unlocking the molecular mechanisms of oncogenic regulation and tumor immune evasion. By combining innovative product design, rigorous validation protocols, standardized production and customer-centric scientific support, we translate technological innovation into clinical impact and research breakthroughs for the global life science community. Our ultimate goal is to be the trusted partner of clinical pathologists, researchers and biopharmaceutical professionals worldwide, empowering them to push the boundaries of scientific discovery, advance precision medicine and improve patient outcomes.

Related Product List: ANT BIO PTE. LTD. IHC Kits (Absin) & c-Myc Antibodies (Starter)

All ANT BIO PTE. LTD. products are rigorously validated for sensitivity, specificity, batch consistency and application performance, with comprehensive technical documentation, optimized protocols and expert scientific support. The IHC kits and c-Myc antibodies are designed for seamless integration, forming a powerful toolchain for c-Myc IHC detection and comprehensive tumor research.

Absin IHC Detection Kits (Universal HRP-DAB)

Starter c-Myc Recombinant Rabbit Monoclonal Antibodies

For detailed product specifications, full validation data packages, optimized IHC protocols for c-Myc detection, custom antibody development services, or free sample testing requests, please visit the official website of ANT BIO PTE. LTD. or contact our global sales team for a personalized quote and professional technical consultation. Our experienced team of clinical pathologists, tumor biologists and immunologists provides customized support for experimental design, complex sample analysis, preclinical drug development and clinical pathological testing.

AI Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content in this article involves copyright infringement, intellectual property disputes, or other legal issues, please notify ANT BIO PTE. LTD. immediately. We promise to verify, correct, or remove the relevant content in a timely manner without delay.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.